Open Programme

5th European Drug Policy Forum

The new framework for innovation: Has the time come to amend the regulation in Europe?

Madrid, 25th May 2009.
Ernst Lluch Auditorium
Carlos III Health Institute
Sinesio Delgado, 10
28029 – Madrid

Why does this matter?

In 1965, European companies developed 65% of new molecules marketed in the world. Forty-five years later that percentage had fallen to 33%, primarily in U.S.

Few analysts would last from the need to strengthen the competitiveness of the pharmaceutical industry in Europe to promote the attraction of innovative companies through tax incentives, improving the entry of the innovations that really worthwhile and laying the foundations for a scientific system of high quality. Of course, with the necessary financial stability of health policies of member states.

In the current model, the cooperation between EU member countries for the promotion of innovation is difficult. National governments control prices, and although there is a certain tendency towards homogenization, there is still a way to go. Transparency Directive in 1989 which provided guidelines for the pricing and reimbursement mechanisms at the national level is taking longer to become operational. Decisions remain opaque in most countries except the UK and Germany. The issue of parallel trade, but not considered legal in terms of economics and innovation seems to have no solution. The use of economic evaluation techniques to aid the fixing of prices is neglected in many EU countries to the field of good intentions.

Referred to Spain, the performance of innovation produced by institutions of higher education is still low, averaging 3.6 per university licenses a year, generating 45,000 € / year / college, compared to 11.2 at the European level , which generate 266,800 € / year / college, and 26.3 in the U.S., which in turn generate 7 million euros per year for each university. Moreover, the knowledge generated in R & D by the major Spanish companies is low compared to other EU countries.

Europe needs to emerge stronger from the deep economic crisis through the conviction and faith of its citizens in the benefits of integration. Our commitment to innovation as an engine of growth in a continent with few natural resources is imperative. Reinforce how much built in terms of social welfare requires robust and sustained economic growth, an improvement of the competitiveness of businesses and governments.

Lastly, the business environment can be managed so as to assist innovators to capture value of innovation. Management actions, whether from businesses large and small, can set the role of intellectual property and the technology to define the appropriate system architecture sector. There is no doubt that the future goals, strategy and resources, helping to determine the distribution of benefits from innovation. For example, a company that supports making public the sequences of human genes expressed, prevents the privatization of the genes that could block their future research goals, so it is not always the system design of appropriate means to strengthen intellectual property rights. These and other topics will be discussed in an open, relaxed and friendly as it has been doing the past four years.


José J. Navas
Antonio Tataranni
Joan Rovira
Stefano Bertuzzi
Laura Cabiedes
Joel Jean-Mairet
Carlos Cordón-Cardó
Gabriel Elorriaga


9:00 h / 9:15 h:


9:15 h / 9:30 h:


    Ms. Regina Múzquiz, Head of Institutional Relations, Sanofi-aventis Spain.
    Mr. José J. Navas, Director of Instituto de Salud Carlos III, Ministry of Science and Innovation.
    Mr. Alfonso Jiménez, General Director of Pharmacy, Ministry oh Health and Social Policy
9:30 h / 11:00 h:

First Panel
"Crossroads in Healthcare Innovation: new frameworks in the EU and the U.S."

    Mr. Antonio Tataranni, Head of Medical Affairs Europe & Canada, Sanofi Aventis
    Mr. Joan Rovira, Professor Emeritus, University of Barcelona
    Mr. Stefano Bertuzzi, Office of the Director, Office of Science Policy, National Institutes of Health, Bethesda, MD, EEUU
    Moderator: Mr. Jesús Millán, President of Gaspar Casal Foundation.

11:00 h / 11:30 h:


11:30 h / 13:00 h:

Second Panel
"The future of innovation in Spain: the visions of the different actors"

    The vision of the Ministry of Science and Innovation. Mr. Carlos Martínez, Undersecretary of Research, Ministry of Science and Innovation.
    The vision of the University. MS. Laura Cabiedes. Professor Applied Economics. University of Oviedo.
    The vision of the investor. Mr. Joel Jean-Mairet. CEO Ysios Capital Partners.
    The vision of the basic and applied researcher. Carlos Cordon-Cardó, Professor and Vice-Chair, Department of Pathology, Professor and Member, Department of Urology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University
    Moderator: Ms. Regina Múzquiz, Head of Institutional Relations, Sanofi-aventis Spain.
11:30 h / 13:00 h:

Third Panel
"The role of legislators in Spain"

    Popular Party: Mr. Gabriel Elorriaga. MP and spokesman of PP in the Commission on Science and Innovation.
    Socialist Party: Mr. Joan Callabuig, MP and spokesman of PSOE in the Commission on Science and Innovation.
    Moderator: Mr. Juan del Llano, CEO Gaspar Casal Foundation.
14:15 h / 14:30 h:

Mr. Evert van Oosterum, CEO Sanofi aventis, Spain.
Mr. Jesús Millán, President of Gaspar Casal Foundation.
Ms. Trinidad Jiménez, Minister of Health and Social Policy, Spanish Government.*

* tbc

14:30 h:



Photo gallery

[ Others Forum ]